Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Jun 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Apr 2022 Results assessing the demographic, clinical, and molecular characteristics of three adult subjects receiving ONC-201, presented at the 74th Annual Meeting of the American Academy of Neurology 2022.
19 Nov 2021 According to the Chimerix media release, positive data from its 50-patient efficacy analysis from ONC006, ONC013, ONC014, ONC016, or ONC018 studies will be presented at the Society for Neuro-Oncology (SNO) Annual Meeting 2021.
19 Nov 2021 Pooled data presented in a Chimerix media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com